NCT03382262View on ClinicalTrials.gov

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

October 9, 2018

Study Completion Date

October 9, 2018

Conditions
Osteoarthritis of the ShoulderOsteoarthritis of the Hip
Interventions
DRUG

FX006 32 mg

Extended-release 32 mg FX006 IA injection

DRUG

TAcs 40 mg

Immediate-release 40mg TAcs IA injection

Trial Locations (6)

14609

Rochester Clinical Research, Rochester

16635

Altoona Center for Clinical Research, Duncansville

90509

LA Biomed at Harbor-UCLA Medical Center, Torrance

91942

Biosolutions Clinical Research Center, La Mesa

92020

TriWest Research Associates, LLC, El Cajon

92103

Artemis Institute for Clinical Research, San Diego

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY